The 10-year survival rate for patients with metastatic melanoma is less than 10%. Although
surgery and radiation therapy have a role in the treatment of metastatic disease, systemic …

Background Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of
its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune …

Background Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated
with encouraging overall survival in uncontrolled studies involving previously treated …

Chronic immunosuppression in solid organ transplant recipients (SOTRs) leads to an
increased risk of a wide variety of cancers. Immune checkpoint inhibitor (ICI) therapy is …

Background In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab
showed superior efficacy over sunitinib in patients with previously untreated intermediate …

Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We
have undertaken a genomics based, hypothesis driving, approach to query an emerging …

Background CheckMate 025 has shown superior efficacy for nivolumab over everolimus in
patients with advanced renal cell carcinoma (aRCC) along with improved safety and …

This single-arm, phase I dose-escalation trial (NCT02983045) evaluated
bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus …

Long-term engraftment of allogeneic cells necessitates eluding immune-mediated rejection,
which is currently achieved by matching for human leukocyte antigen (HLA) expression …

Purpose: Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC)
have poor prognoses and suboptimal outcomes with targeted therapy. This post hoc …